Cargando…

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment

The ongoing global pandemic of COVID-19 poses unprecedented public health risks for governments and societies around the world, which have been exacerbated by the emergence of SARS-CoV-2 variants. Pharmaceutical interventions with high antiviral efficacy are expected to delay and contain the COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Yuan, Shen, Mingwang, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031952/ https://www.ncbi.nlm.nih.gov/pubmed/35458493 http://dx.doi.org/10.3390/v14040763

Ejemplares similares

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
por: Singla, Shivali, et al.
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2023)

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022)

Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
por: McIntosh, John A., et al.
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir
por: Burke, Ashleigh J., et al.
Publicado: (2022)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
por: Benaicha, Karima, et al.
Publicado: (2023)

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
por: Mali, Kalpana Ramanna, et al.
Publicado: (2022)

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
por: Guermazi, Dorra, et al.
Publicado: (2023)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Review on molnupiravir as a promising oral drug for the treatment of COVID-19
por: Zarenezhad, Elham, et al.
Publicado: (2022)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
por: Painter, George R, et al.
Publicado: (2021)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression
por: Vena, Antonio, et al.
Publicado: (2022)

Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients
por: Poznański, Paweł, et al.
Publicado: (2022)

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
por: De Vito, Andrea, et al.
Publicado: (2022)

Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis
por: Gopalsamuthiram, Vijayagopal, et al.
Publicado: (2021)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Tian, Fangyuan, et al.
Publicado: (2023)

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
por: Kamal, Lina, et al.
Publicado: (2022)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

(349) Molnupiravir vs Remdesivir for Treatment of Covid-19 in Lung Transplant Recipients
por: Razia, D., et al.
Publicado: (2023)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ij4msuc28sq1g8h238todthas